Advice
Following a resubmission.
Frovatriptan (Migard) is accepted for use within NHS Scotland for treatment of the headache phase of migraine attacks with or without aura.
It is the seventh 5-HT1 agonist to be marketed in the UK for this indication. It is less effective at rapidly relieving migraine when compared with the most commonly prescribed drug in this class, but has a similar duration of effect. It is also less expensive than other 5-HT1 agonists.
Download detailed advice25KB (PDF)
Medicine details
- Medicine name:
- Frovatriptan (Migard)
- SMC ID:
- 49/03
- Indication:
- Headache phase of migraine attacks with or without aura
- Pharmaceutical company
- A Menarini Pharmaceuticals UK Ltd
- BNF chapter
- Central nervous system
- Submission type
- Resubmission
- Status
- Accepted
- Date advice published
- 09 February 2004